Literature DB >> 1997112

Phase II trial of trimelamol in refractory ovarian cancer.

I R Judson1, A H Calvert, M E Gore, K Balmanno, L A Gumbrell, T Perren, E Wiltshaw.   

Abstract

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1997112      PMCID： PMC1971798          DOI： 10.1038/bjc.1991.72

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  In vitro studies with hexamethylmelamine.

Authors:  C J Rutty; T A Connors
Journal:  Biochem Pharmacol       Date:  1977-12-15       Impact factor: 5.858

2.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson
Journal:  Gynecol Oncol       Date:  1990-02       Impact factor: 5.482

3.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Authors:  I R Judson; A H Calvert; C J Rutty; G Abel; L A Gumbrell; M A Graham; B D Evans; D E Wilman; S E Ashley; F Cairnduff
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

5.  Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Authors:  D Cunningham; J Hawthorn; A Pople; J C Gazet; H T Ford; T Challoner; R C Coombes
Journal:  Lancet       Date:  1987-06-27       Impact factor: 79.321

6.  In vitro cytotoxicity of the methylmelamines.

Authors:  C J Rutty; G Abel
Journal:  Chem Biol Interact       Date:  1980-02       Impact factor: 5.192

7.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

Authors:  G Blackledge; F Lawton; C Redman; K Kelly
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

8.  Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.

Authors:  I R Judson; C J Rutty; G Abel; M A Graham
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

9.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

Authors:  J Bermudez; E A Boyle; W D Miner; G J Sanger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640
  9 in total
  1 in total

1.  CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

Authors:  J H Beijnen; K P Flora; G W Halbert; R E Henrar; J A Slack
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.